Immunovant, Inc.IMVT

Immunovant, Inc. Segments Disclosure

10-KFiled May 20, 20262 min read
Segment Information
The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates. The determination of a single segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its chief executive officer. The CODM, in alignment with the Company’s strategic goals, uses consolidated net loss to monitor budget to actual results and cash forecast models for assessing performance and making operating decisions. The measurement of segment assets is reported on the consolidated balance sheet as total assets.

The Company’s significant segment expenses are as follows (in thousands):

Years Ended March 31,
202620252024
Therapeutic area-specific research and development:
Endocrine diseases$90,359 $63,073 $33,205 
Neurological diseases82,515 93,224 41,060 
Rheumatology diseases48,813 23,897 — 
Dermatology diseases20,264 15,633 — 
Other clinical and nonclinical3,367 9,327 39,811 
Other unallocated research and development43,856 44,264 24,562 
Contractual costs related to batoclimab program discontinuation38,952 — — 
Personnel-related research and development (1)
128,534 111,499  74,290 
Acquired in-process research and development— — 12,500 
Personnel-related general and administrative (2)
48,730 41,095  34,684 
Other general and administrative (3)
27,512 36,140 22,597 
Interest income, net(25,330)(24,732)(24,948)
Other segment items (4)
(1,966)420 1,575 
Net loss$505,606 $413,840 $259,336 
___________
(1)Includes stock-based compensation expense of $29,712, $27,014 and $20,409 for the years ended March 31, 2026, 2025 and 2024, respectively
(2)Includes stock-based compensation expense of $26,012, $22,473 and $20,707 for the years ended March 31, 2026, 2025 and 2024, respectively
(3)Other general and administrative expenses primarily include legal and other professional fees, information technology costs and market research costs
(4)Other segment items include other (income) expense, net and provision for income taxes

Historical Timeline

Fiscal YearFiled
2026May 20, 2026Showing above
2025May 29, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesLeasesCommitmentsStock CompensationNew StandardsPay vs Performance